Shots:

• The discontinuation is based on the interim analysis of data from the CIRRUS-1 study demonstrating that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant
• In the study- both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy- mycophenolate and corticosteroids)
• The company will continue the study of CFZ533 in liver transplant as the studies are exploring the potential treatment in other conditions- such as hidradenitis suppurativa and Sjögren’s syndrome

Ref: Novartis | Image: Novartis